Road to unmanned driving

Texas forms task force geared at autonomous vehicle development

TxDOT has a new task force focused on keeping Texans informed on self-driving vehicles that are getting road ready. Getty Images

Self-driving cars are en route to Texas, and the state government wants to ensure Texas is ready for the ride. The Texas Department of Transportation announced the creation of a Connected and Autonomous Vehicle Task Force on Jan. 24.

The CAV Task Force will focus on being a comprehensive resource for information on all Texas CAV projects, investments, and initiatives, the press release says. The organization will also host events surrounding CAV progress and education around the topic.

"With our world-class universities, top-notch workforce and startup culture, Texas is a national leader in the development of new technologies," says Gov. Greg Abbott in the release. "As transportation technology advances, the CAV Task Force will ensure that the Lone Star State remains at the forefront of innovation."

TxDOT's interest, the release reports, is in hopes that the self-driving technology will minimize accidents and maximize safety, as well as expand opportunities for residents, especially within the elderly and disabled populations who currently don't have reliable transportation to their errands and appointments.

In 2017, in the 85th Texas Legislative Session, Abbot signed Senate Bill 2205 into law. The legislation identifies key requirements for CAVs, such as insurance and adhering to traffic laws, like normal vehicles, as well as requiring video recording devices in the car, the Texas Tribune reported. However, it's worth nothing that self-driving vehicles were already being experimented with in Austin by the likes of Google, the Tribune notes.

"Our goal is to further build on the momentum already established with the Texas Technology Task Force and the Texas Innovation Alliance, and work with interested parties on the latest and greatest in CAV projects and enhancements," says TxDOT Executive Director James Bass. "We look forward to furthering these important efforts as connected and autonomous vehicles become reality."

TxDOT is also focusing on rail planning, as the Houston-Dallas high-speed rail chugs along. Earlier this month, the state asked for Texans' feedback on the projects.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted